401 related articles for article (PubMed ID: 18832444)
41. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
42. Familial nonmedullary thyroid carcinoma-clinical relevance and prognosis. A European multicenter study. ESES Vienna presentation.
Hillenbrand A; Varhaug JE; Brauckhoff M; Pandev R; Haufe S; Dotzenrath C; Köberle R; Hoffmann R; Klein G; Kadmon M; Negele T; Hagieva T; Henne-Bruns D; Luster M; Weber T
Langenbecks Arch Surg; 2010 Sep; 395(7):851-8. PubMed ID: 20683623
[TBL] [Abstract][Full Text] [Related]
43. [Familial occurrence of papillary thyroid carcinoma].
Suzuki S; Watanabe I
Gan No Rinsho; 1985 Apr; 31(4):414-9. PubMed ID: 4009973
[TBL] [Abstract][Full Text] [Related]
44. Cribriform-morular variant of papillary carcinoma: the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma. A case report with clinical and molecular genetic correlation.
Ng SB; Sittampalam K; Goh YH; Eu KW
Pathology; 2003 Feb; 35(1):42-6. PubMed ID: 12701683
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
Milas M; Barbosa GF; Mitchell J; Berber E; Siperstein A; Gupta M
Ann Surg Oncol; 2009 Feb; 16(2):473-80. PubMed ID: 19015922
[TBL] [Abstract][Full Text] [Related]
46. Long-term prognosis of medullary thyroid carcinoma.
Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
[TBL] [Abstract][Full Text] [Related]
47. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci.
Tsilchorozidou T; Vafiadou E; Yovos JG; Romeo G; McKay J; Lesueur F; Bonora E
Thyroid; 2005 Dec; 15(12):1349-54. PubMed ID: 16405407
[TBL] [Abstract][Full Text] [Related]
48. [Clinical factors related to central compartment lymph node metastasis in papillary thyroid microcarcinoma: clinical analysis of 117 cases].
Shao Y; Cai XJ; Gao L; Li H; Xie L
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(6):403-5. PubMed ID: 19567120
[TBL] [Abstract][Full Text] [Related]
49. [Clinical features of 17 patients with familial non medullary thyroid carcinoma].
Mosso L; Velasco S; Salazar I; Solar A; González H; Cardona B; Fardella C; González G; López JM; Rodríguez JA; Cruz F; Arteaga E
Rev Med Chil; 2007 Jun; 135(6):718-24. PubMed ID: 17728897
[TBL] [Abstract][Full Text] [Related]
50. Routine bilateral central lymph node clearance for papillary thyroid cancer.
Sadowski BM; Snyder SK; Lairmore TC
Surgery; 2009 Oct; 146(4):696-703; discussion 703-5. PubMed ID: 19789029
[TBL] [Abstract][Full Text] [Related]
51. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma.
Yu XM; Lo CY; Lam AK; Leung P; Luk JM
Ann Surg; 2008 Mar; 247(3):483-9. PubMed ID: 18376194
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathologic features of familial nonmedullary thyroid carcinoma.
Fan YF; Zhang B; Yang X; Shang ZH; Liu HF; Xie Y; Liu YW; Gao WS; Wu Q; Li XY
Chin Med J (Engl); 2015 Apr; 128(8):1037-41. PubMed ID: 25881596
[TBL] [Abstract][Full Text] [Related]
53. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma.
Michels JJ; Jacques M; Henry-Amar M; Bardet S
Hum Pathol; 2007 Feb; 38(2):212-9. PubMed ID: 17097131
[TBL] [Abstract][Full Text] [Related]
54. Familial Non-Medullary Thyroid Cancer Represents an Independent Risk Factor for Increased Cancer Aggressiveness: A Retrospective Analysis of 74 Families.
Tavarelli M; Russo M; Terranova R; Scollo C; Spadaro A; Sapuppo G; Malandrino P; Masucci R; Squatrito S; Pellegriti G
Front Endocrinol (Lausanne); 2015; 6():117. PubMed ID: 26284028
[TBL] [Abstract][Full Text] [Related]
55. [The characteristics of papillary thyroid cancer lymph node metastasis and the clinical significance of central region cervical lymph node dissection].
Li Z; Qu XC; Cheng B
Zhonghua Wai Ke Za Zhi; 2008 Sep; 46(18):1407-9. PubMed ID: 19094514
[TBL] [Abstract][Full Text] [Related]
56. The relation between pure papillary and follicular variant in papillary thyroid carcinoma.
Yuksel O; Kurukahvecioglu O; Ege B; Ekinci O; Aydin A; Poyraz A; Tezel E; Taneri F
Endocr Regul; 2008 Mar; 42(1):29-33. PubMed ID: 18333702
[TBL] [Abstract][Full Text] [Related]
57. Extent of thyroidectomy and lymphadenectomy in 254 patients with papillary thyroid microcarcinoma: a single-institution experience.
Besic N; Zgajnar J; Hocevar M; Petric R
Ann Surg Oncol; 2009 Apr; 16(4):920-8. PubMed ID: 19189188
[TBL] [Abstract][Full Text] [Related]
58. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Cancer Control; 2006 Apr; 13(2):106-10. PubMed ID: 16735984
[TBL] [Abstract][Full Text] [Related]
59. [Papillary thyroid carcinoma: clinical manifestations, recurrences and prognosis].
Hay ID
Vestn Khir Im I I Grek; 2006; 165(1):43-5. PubMed ID: 16568855
[TBL] [Abstract][Full Text] [Related]
60. The long term outcome of papillary thyroid carcinoma patients without primary central lymph node dissection: expected improvement of routine dissection.
Giles Senyurek Y; Tunca F; Boztepe H; Alagöl F; Terzioglu T; Tezelman S
Surgery; 2009 Dec; 146(6):1188-95. PubMed ID: 19958948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
